Repeat Versus Single Quadratus Lumborum Block to Reduce Opioids After Open Sarcoma Resection (RESQU-SARC): A Randomized Clinical Trial

Objective: The primary aim was to compare the discharge prescription oral morphine equivalents (OME) between 2 postoperative analgesia bundles, distinguished by receipt of a single-block versus a second-block. Secondary outcomes included patient-reported outcomes and persistent opioid use. Background: Persistent opioid use after cancer surgery can often be predicted by the volume of the initial outpatient prescription at discharge. Our historical discharge OME for open sarcoma resection was 300 mg. We hypothesized an opioid-reduction bundle with a second-block on postoperative day (POD)4 could decrease OME at discharge. Methods: This was a pragmatic single-institution, unblinded, phase II randomized clinical trial analyzed by intent-to-treat and post hoc Bayesian analyses. Patients undergoing open sarcoma resection who remained hospitalized through POD3 with ongoing opioid requirements were randomized 1:1 on POD3 to receive a standardized opioid-reduction bundle, with or without the addition of a second-block on POD4. Discharge opioid prescriptions used the “5x-multiplier” (5 times patient’s last 24-hour OME) algorithm. Results: Eighty-four patients were randomized (62% male; median age 62 years; median 5-day hospital stay) and were included in the intention-to-treat analysis (41 second-block, 43 single-block). By intent-to-treat, the second-block patients received similar OME on discharge (25 mg vs 50 mg; P = 0.26). Three evaluable second-block patients did not receive the intended second-block. Patients in both arms had similar patient-reported outcomes at discharge and 1-month follow-up. Post hoc Bayesian analysis showed a 90% likelihood of opioid-free discharge for the second-block versus single-block arm. Conclusions: This phase II randomized trial demonstrated feasibility and safety of a planned POD4 second block within a standardized opioid-reduction bundle after open sarcoma resection, but did not meet its primary endpoint of reduced discharge opioid prescriptions. The null frequentist result may be due to an underpowered design, as institutional opioid-sparing efforts reduced baseline consumption more than anticipated. Post hoc Bayesian analysis indicated a high posterior probability (90%) that opioid-free discharge was more likely with the second block bundle, a hypothesis-generating finding that should be confirmed in an adequately powered trial. Routine second blocks are not necessary for all patients, but may warrant consideration in selected individuals with ongoing opioid requirements on POD4.

Authors

Institutions

Publication Details

Journal
Annals of Surgery Open
Published
2026-11-18
DOI
https://doi.org/10.1097/as9.0000000000000725
Primary Topic
Anesthesia and Pain Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Repeat Versus Single Quadratus Lumborum Block to Reduce Opioids After Open Sarcoma Resection (RESQU-SARC): A Randomized Clinical Trial

Matthew H. G. Katz, Christopher P. Scally, Jonathan A. Wilks, Elsa Melissa Arvide et al.
3 links
Annals of Surgery Open
Anesthesia and Pain Management
article

Repeat Versus Single Quadratus Lumborum Block to Reduce Opioids After Open Sarcoma Resection (RESQU-SARC): A Randomized Clinical Trial

Matthew H. G. Katz, Christopher P. Scally, Jonathan A. Wilks, Elsa Melissa Arvide, Keyuri U. Popat, Nikita F. Rajkot, Shannon Hancher‐Hodges, José Soliz, Whitney L. Dewhurst, Timothy Eric Newhook, Ching-Wei David Tzeng, Emily Zhi-Yun Keung, Hyunsoo Hwang, Christina Lynn Roland, Anneliese N. Hierl, Xuemei Wang, Barbra Bryce Speer
article en

Abstract

Objective: The primary aim was to compare the discharge prescription oral morphine equivalents (OME) between 2 postoperative analgesia bundles, distinguished by receipt of a single-block versus a second-block. Secondary outcomes included patient-reported outcomes and persistent opioid use. Background: Persistent opioid use after cancer surgery can often be predicted by the volume of the initial outpatient prescription at discharge. Our historical discharge OME for open sarcoma resection was 300 mg. We hypothesized an opioid-reduction bundle with a second-block on postoperative day (POD)4 could decrease OME at discharge. Methods: This was a pragmatic single-institution, unblinded, phase II randomized clinical trial analyzed by intent-to-treat and post hoc Bayesian analyses. Patients undergoing open sarcoma resection who remained hospitalized through POD3 with ongoing opioid requirements were randomized 1:1 on POD3 to receive a standardized opioid-reduction bundle, with or without the addition of a second-block on POD4. Discharge opioid prescriptions used the “5x-multiplier” (5 times patient’s last 24-hour OME) algorithm. Results: Eighty-four patients were randomized (62% male; median age 62 years; median 5-day hospital stay) and were included in the intention-to-treat analysis (41 second-block, 43 single-block). By intent-to-treat, the second-block patients received similar OME on discharge (25 mg vs 50 mg; P = 0.26). Three evaluable second-block patients did not receive the intended second-block. Patients in both arms had similar patient-reported outcomes at discharge and 1-month follow-up. Post hoc Bayesian analysis showed a 90% likelihood of opioid-free discharge for the second-block versus single-block arm. Conclusions: This phase II randomized trial demonstrated feasibility and safety of a planned POD4 second block within a standardized opioid-reduction bundle after open sarcoma resection, but did not meet its primary endpoint of reduced discharge opioid prescriptions. The null frequentist result may be due to an underpowered design, as institutional opioid-sparing efforts reduced baseline consumption more than anticipated. Post hoc Bayesian analysis indicated a high posterior probability (90%) that opioid-free discharge was more likely with the second block bundle, a hypothesis-generating finding that should be confirmed in an adequately powered trial. Routine second blocks are not necessary for all patients, but may warrant consideration in selected individuals with ongoing opioid requirements on POD4.

Annals of Surgery OpenVol. 7(4)
The University of Texas MD Anderson Cancer Center (US)
Good health and well-being
Anesthesia and Pain Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon